A Breakthrough from Zhejiang University: Introducing Bone 02 Bone Adhesive

In a remarkable advancement for orthopedic surgery, researchers at Zhejiang University School of Medicine have developed Bone 02, a revolutionary bio-adhesive designed to repair bone fractures in as little as three minutes. This injectable material, inspired by the adhesive properties of oysters, addresses longstanding challenges in treating comminuted fractures—those involving multiple shattered fragments. Traditional methods often require extensive surgery with metal implants, but Bone 02 offers a minimally invasive alternative that bonds fragments securely even in blood-rich environments, promoting natural healing without foreign bodies left behind.

The innovation emerged from the Orthopedics Department at Sir Run Run Shaw Hospital, affiliated with Zhejiang University. Led by Professor Fan Shunwu, a veteran orthopedic surgeon with over 40 years of experience, and Associate Chief Physician Lin Xianfeng, the team overcame a century-old hurdle: creating an adhesive strong enough for wet, dynamic physiological conditions yet fully biodegradable. Named after the popular instant glue '502' in homage to its rapid action, Bone 02 represents China's push in biomedical engineering within higher education institutions.

The Growing Burden of Bone Fractures in China

China faces a surging epidemic of bone fractures, driven by its rapidly aging population and high rates of traffic accidents, falls, and osteoporosis. According to Global Burden of Disease data, vertebral fractures alone affected millions in 2021, with incidence rising steadily. By 2050, over 50% of global osteoporotic hip fractures are projected to occur in Asia, predominantly China due to its demographic shift— the elderly population (70+) expected to double from 138 million in 2025 to 339 million. Facial fractures numbered 1.19 million new cases in 2021, while forearm fractures impose significant disability-adjusted life years (DALYs). Comminuted fractures, common in high-impact trauma, complicate treatment and recovery, straining healthcare resources in a nation with over 1.4 billion people.

Zhejiang University's contribution aligns with national priorities under the Healthy China 2030 initiative, where universities play a pivotal role in translating research into clinical solutions. This development underscores how Chinese higher education is tackling public health crises through interdisciplinary collaboration between clinicians, materials scientists, and engineers.

Limitations of Conventional Fracture Repair Techniques

Standard treatments for bone fractures in China and globally rely on open reduction internal fixation (ORIF) using titanium plates, screws, or intramedullary nails. These methods excel for simple fractures but falter with comminuted ones: small fragments are hard to manipulate, surgery times extend to hours, and implant-related complications like infection (5-10% risk), loosening, or allergic reactions affect up to 20% of cases. Secondary surgeries for implant removal add burden, especially in elderly patients with comorbidities.

In China, where osteoporosis prevalence exceeds 20% among those over 50, implant failures exacerbate recovery challenges. Bone cements like PMMA exist but lack adhesion in wet conditions and aren't biodegradable, leading to stress shielding that weakens surrounding bone. Bone 02 circumvents these by providing immediate, robust fixation without hardware, reducing operative time by 70-80% and incision size to 2-3 cm.

Oyster-Inspired Design: The Science Behind Bone 02

Bone 02 mimics the byssus threads oysters produce to adhere to rocks underwater, combining catechol-modified collagen (for wet adhesion), nano-clay (for reinforcement), and cross-linking agents for rapid polymerization. Upon injection, it gels in seconds, achieving tensile strength over 180 kg (1.8 MPa shear, 10 MPa compression)—twice that of commercial glues—and withstands 400+ pounds of pull force. Fully biodegradable, it degrades in 6 months via hydrolysis and enzymatic action, replaced by new bone tissue.

The formulation promotes osteoimmunomodulation: it scavenges reactive oxygen species (ROS), polarizes macrophages to M2 phenotype for anti-inflammation, and releases growth factors for osteogenesis. Preclinical rabbit/pig models showed faster healing than controls, with superior radiology and biomechanics. This biomimetic approach exemplifies Zhejiang University's strength in bioinspired materials research.

Zhejiang University's Research Ecosystem Driving Innovation

Zhejiang University, a C9 League member and top Chinese research powerhouse, fosters such breakthroughs through its Qiushi Academy and hospital integrations. The project stemmed from Prof. Fan's clinical frustrations, evolving via materials science collaborations. Sir Run Run Shaw Hospital's multidisciplinary teams—orthopedics, biomaterials, immunology—enabled rapid prototyping and testing. This mirrors China's higher ed trend: universities like ZJU secure massive funding (RMB billions annually) for translational medtech, producing 20% of global biomed papers.

Student involvement, including PhD candidates in polymer chemistry, highlights hands-on training, preparing graduates for China's booming medtech sector valued at USD 100B+ by 2026.

Clinical Trials: Promising Results from 150+ Patients

In a multicenter randomized controlled trial launched September 2025, Bone 02 treated over 150 patients with distal radius and other comminuted fractures. Fixation via single 2-3 cm incision took ~3 minutes; 3-month follow-ups showed full union, restored function, zero implant failures or infections. One case: young worker's shattered wrist healed scarlessly, regaining full mobility.

Safety profile excellent: no cytotoxicity, inflammation, or embolism risks. Compared to ORIF, it cut surgery time, blood loss, and hospitalization by 50%. Ongoing trials expand to long bones, spine.Zhejiang University announcement

Mechanical Superiority and Biocompatibility

• Adhesion Strength: >1.8 MPa shear, 10 MPa compression in wet blood.
• Durability: Withstands 98% compression, 600% strain.
• Degradation: 6 months, matching bone remodeling.
• Immunomodulation: ROS scavenging, M2 polarization accelerates healing 2x vs. controls.

Lab tests confirm non-toxicity; animal models show vascular ingrowth and bone regeneration.

Broader Applications and Potential Expansions

Beyond fractures, Bone 02 eyes dental implants, spinal fixation, military/disaster aid. Its portability suits field use. ZJU plans Phase III trials 2026, commercialization via partnerships. Cost savings: reduces reoperations (USD 10K+ per case), ideal for China's 10M+ annual fractures.

China's Higher Education Leading Global Biomed Innovations

ZJU's success spotlights China's university research surge: 985/211 institutions file 50% patents, host 30% biomed trials. Collaborations with hospitals accelerate bench-to-bedside. Peers like Tsinghua, Peking U advance scaffolds, stem cells. Government funding (RMB 400B+ science 2026) fuels this, positioning Chinese academia as medtech leaders.

Challenges, Skepticism, and Path Forward

While promising, experts urge long-term data on load-bearing bones, cost-effectiveness. Viral hype misattributed to Tsinghua, but ZJU's evidence-based approach prevails. Regulatory approval (NMPA) expected 2026; global trials could follow FDA/EMA paths.

Photo by dadalan real on Unsplash

Future Outlook: Transforming Orthopedics Worldwide

Bone 02 heralds minimally invasive era, cutting disabilities, healthcare costs. For Chinese higher ed, it exemplifies talent cultivation, IP generation. Aspiring researchers: pursue biomed eng at ZJU-like hubs for impactful careers. Stay tuned for trials; this glue mends more than bones—higher ed's innovative spirit.